Search

Displaying results 2131 - 2140 of 6949 in total
  1. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

    Categories: Drugs for Acid Related Disorders
  2. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  3. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  4. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    Lindane is still allowed for pharmaceutical use until 2015. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical

  5. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  6. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.

  7. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241030, A241040] Narsoplimab (OMS721), a human IgG4λ anti-MASP-2 antibody, is under consideration as a treatment for hematopoietic stem cell transplant-associated TMA (HSCT-TMA/TA-TMA) and IgA nephropathy

  8. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  9. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. … Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.

    Categories: Nasal Decongestants for Systemic Use, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Target

    Alpha-2 adrenergic receptors

    go.drugbank.com/bio_entities/BE0004864
    TargetHumans

    Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (...

    Polypeptides: Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptorSynonyms: Alpha-2 adrenergic receptor subtype C10, Alpha-2 adrenergic receptor subtype C2